Expression of B7-H3 in hypopharyngeal squamous cell carcinoma as a predictive indicator for tumor metastasis and prognosis

International Journal of Oncology

Volumn 38, Issue 5, 2011, Pages 1219-1226

  Katayama, Akihiro ^a   Takahara, Miki ^a   Kishibe, Kan ^a   Nagato, Toshihiro ^a   Kunibe, Isamu ^a   Katada, Akihiro ^a   Hayashi, Tatsuya ^a   Harabuchi, Yasuaki ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

B7 H3; Co regulatory factor; Hypopharynx; Prognostic factor; Squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; B7 ANTIGEN; B7 H3 ANTIGEN; CELL SURFACE PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CD8+ T LYMPHOCYTE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; IMMUNOHISTOLOGY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MALE; METASTASIS POTENTIAL; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; SQUAMOUS CELL CARCINOMA; STAINING; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RECEPTORS, IMMUNOLOGIC;

EID: 79954990698     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.949     Document Type: Article

References (46)

1. Wycliffe ND, Grover RS, Kim PD and Simental A Jr: Hypopharyngeal cancer. Top Magn Reson Imaging 18: 243-258, 2007. (Pubitemid 47480728)
2. Hall SF, Groome PA, Irish J and O'Sullivan B: The natural history of patients with squamous cell carcinoma of the hypopharynx. Laryngoscope 118: 1362-1371, 2008.
3. Hoffman HT, Karnell LH, Shah JP, et al: Hypopharyngeal cancer patient care evaluation. Laryngoscope 107: 1005-1017, 1997. (Pubitemid 27335251)
4. Kraus DH, Zelefsky MJ, Brock HA, Huo J, Harrison LB and Shah JP: Combined surgery and radiation therapy for squamous cell carcinoma of the hypopharynx. Otolaryngol Head Neck Surg 116: 637-641, 1997. (Pubitemid 27355236)
5. Thompson RH, Dong H, Lohse CM, et al: PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 13: 1757-1761, 2007. (Pubitemid 46952942)
6. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K and Ueda S: Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 56: 1173-1182, 2007. (Pubitemid 46763932)
7. Inman BA, Sebo TJ, Frigola X, et al: PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCGCG-induced granulomata: associations with localized stage progression. Cancer 109: 1499-1505, 2007. (Pubitemid 46595684)
8. Krambeck AE, Thompson RH, Dong H, et al: B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci USA 103: 10391-10396, 2006. (Pubitemid 44051177)
9. Hirano F, Kaneko K, Tamura H, et al: Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65: 1089-1096, 2005. (Pubitemid 40216472)
10. Thompson RH, Kuntz SM, Leibovich BC, et al: Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66: 3381-3385, 2006.
11. Thompson RH, Webster WS, Cheville JC, et al: B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. Urology 66: 10-14, 2005. (Pubitemid 41356553)
12. Thompson RH, Gillett MD, Cheville JC, et al: Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 101: 17174-17179, 2004. (Pubitemid 39627793)
13. Zang X, Thompson RH, Al-Ahmadie HA, et al: B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA 104: 19458-19463, 2007.
14. Dong H, Strome SE, Salomao DR, et al: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800, 2002.
15. Dong H, Zhu G, Tamada K and Chen L: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5: 1365-1369, 1999.
16. Uppaluri R, Dunn GP and Lewis JS Jr: Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun 8: 16, 2008.
17. Whiteside TLTL: The tumor microenvironment and its role in promoting tumor growth. Oncogene 27: 5904-5912, 2008.
18. Cho Y, Miyamoto M, Kato K, et al: CD4+ and CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell carcinoma. Cancer Res 63: 1555-1559, 2003. (Pubitemid 36373643)
19. Eerola AKAK, Soini Y and Paakko P: A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin Cancer Res 6: 1875-1881, 2000.
20. Naito Y, Saito K, Shiiba K, et al: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58: 3491-3494, 1998. (Pubitemid 28376536)
21. Brandwein-Gensler M, Teixeira MS, Lewis CM, et al: Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol 29: 167-178, 2005. (Pubitemid 40170634)
22. Chapoval AIAI, Ni J, Lau JS, et al: B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2: 269-274, 2001. (Pubitemid 33706005)
23. Luo L, Chapoval AI, Flies DB, et al: B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J Immunol 173: 5445-5450, 2004. (Pubitemid 39392128)
24. Lupu CM, Eisenbach C, Kuefner MA, et al: An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo. J Gastrointest Surg 10: 635-645, 2006. (Pubitemid 43711146)
25. Ma L, Luo L, Qiao H, et al: Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. J Hepatol 46: 98-106, 2007. (Pubitemid 44827415)
26. Sun X, Vale M, Leung E, Kanwar JRJR, Gupta R and Krissansen GW: Mouse B7-H3 induces antitumor immunity. Gene Ther 10: 1728-1734, 2003. (Pubitemid 37121044)
27. Castriconi R, Dondero A, Augugliaro R, et al: Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci USA 101: 12640-12645, 2004. (Pubitemid 39122076)
28. Suh WK, Gajewska BU, Okada H, et al: The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol 4: 899-906, 2003. (Pubitemid 37098661)
29. Prasad DV, Nguyen T, Li Z, et al: Murine B7-H3 is a negative regulator of T cells. J Immunol 173: 2500-2506, 2004. (Pubitemid 39063108)
30. Yamato I, Sho M, Nomi T, et al: Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer 101: 1709-1716, 2009.
31. Sun Y, Wang Y, Zhao J, et al: B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 53: 143-151, 2006. (Pubitemid 43994236)
32. R Roth TJ, Sheinin Y, Lohse CM, et al: B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 67: 7893-7900, 2007. (Pubitemid 47281385)
33. Gregorio A, Corrias MV, Castriconi R, et al: Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7-H3 surface molecule. Histopathology 53: 73-80, 2008. (Pubitemid 351861985)
34. Crispen PL, Sheinin Y, Roth TJTJ, et al: Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 14: 5150-5157, 2008.
35. Sun J, Chen LJLJ, Zhang GB, et al: Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother 59: 1163-1171, 2010.
36. Robbins KT, Storniolo AM, Kerber C, et al: Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol 12: 2113-2120, 1994.
37. Robbins KT, Kumar P, Regine WF, et al: Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: the Memphis experience. Int J Radiat Oncol Biol Phys 38: 263-271, 1997. (Pubitemid 27318641)
38. Robbins KT, Kumar P, Wong FS, et al: Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck 22: 687-693, 2000.
39. King RG, Herrin BR and Justement LB: Trem-like transcript 2 is expressed on cells of the myeloid/granuloid and B lymphoid lineage and is up-regulated in response to inflammation. J Immunol 176: 6012-6021, 2006.
40. Klesney-Tait J, Turnbull IR and Colonna M: The TREM receptor family and signal integration. Nat Immunol 7: 1266-1273, 2006. (Pubitemid 46111244)
41. Hashiguchi M, Kobori H, Ritprajak P, Kamimura Y, Kozono H and Azuma M: Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc Natl Acad Sci USA 105: 10495-10500, 2008.
42. Distel LV, Fickenscher R, Dietel K, et al: Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: prognostic impact may depend on type of treatment and stage of disease. Oral Oncol 45: e167-174, 2009.
43. Watanabe Y, Katou F, Ohtani H, Nakayama T, Yoshie O and Hashimoto K: Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109: 744-752, 2010.
44. Zang X and Allison JP: The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 13: 5271-5279, 2007. (Pubitemid 47510350)
45. Chavin G, Sheinin Y, Crispen PL, et al: Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res 15: 2174-2180, 2009.
46. Kramer K, Kushner BH, Modak S, et al: Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol 97: 409-418, 2010.